WIPO Re:Search: Accelerating anthelmintic development through cross-sector partnerships  by Ramamoorthi, Roopa et al.
International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 220–225Contents lists available at ScienceDirect
International Journal for Parasitology:
Drugs and Drug Resistance
journal homepage: www.elsevier .com/ locate/ i jpddrInvited ReviewWIPO Re:Search: Accelerating anthelmintic development through
cross-sector partnershipshttp://dx.doi.org/10.1016/j.ijpddr.2014.09.002
2211-3207/ 2014 Australian Society for Parasitology. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
⇑ Corresponding author. Tel.: +1 206 732 2131.
E-mail addresses: rramamoorthi@bvgh.org (R. Ramamoorthi), jdent@bvgh.org
(J. Dent).Roopa Ramamoorthi, Katy M. Graef, Jennifer Dent ⇑
BIO Ventures for Global Health, 401 Terry Avenue North, Seattle, WA 98109, United States
a r t i c l e i n f oArticle history:





Anthelmintica b s t r a c t
Neglected tropical diseases (NTDs), malaria, and tuberculosis have a devastating effect on an estimated
1.6 billion people worldwide. The World Intellectual Property Organization (WIPO) Re:Search consortium
accelerates the development of new drugs, vaccines, and diagnostics for these diseases by connecting the
assets and resources of pharmaceutical companies, such as compound libraries and expertise, to aca-
demic or nonproﬁt researchers with novel product discovery or development ideas. As the WIPO
Re:Search Partnership Hub Administrator, BIO Ventures for Global Health (BVGH) ﬁelds requests from
researchers, identiﬁes Member organizations able to fulﬁll these requests, and helps forge mutually ben-
eﬁcial collaborations. Since its inception in October 2011, WIPO Re:Search membership has expanded to
more than 90 institutions, including leading pharmaceutical companies, universities, nonproﬁt research
institutions, and product development partnerships from around the world. To date, WIPO Re:Search has
facilitated over 70 research agreements between Consortium Members, including 11 collaborations
focused on anthelmintic drug discovery.
 2014 Australian Society for Parasitology. Published by Elsevier Ltd. This is an open access article under
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Interest in, and support for, global health have surged in the
past 20 years (Institute for Health Metrics and Evaluation, 2012).
The public, private, and civil sectors have recognized the burden
that diseases of poverty have on the global economy, as well as
the economic growth that could be realized by alleviating the
impact that these diseases exact on individuals and communities
in low- and middle-income countries (World Bank, 1993). In
2010, the World Health Organization proﬁled 17 diseases it
deemed to be ‘‘neglected’’ – diseases that disproportionately affect
the poor, cause signiﬁcant morbidity and mortality, and lack safe,effective, and affordable drugs, vaccines, and diagnostics (Savioli
and Daumerie, 2010; Smith and Taylor, 2013). These neglected
tropical diseases (NTDs) infect over a billion individuals worldwide
and negatively affect the lives of many more (Hotez et al., 2014). A
variety of approaches have been employed to combat these dis-
eases, including education, vector control, sanitation and hygiene,
behavioral change, and mass drug administration (MDA) programs.
In addition, several initiatives have been established to stimulate
and support the development of new products for these 17
diseases. These initiatives include product development partner-
ships (PDPs), such as the Drugs for Neglected Diseases initiative
(DNDi) and the Sabin Vaccine Institute, as well as the Uniting to
Combat NTDs coalition and the WIPO Re:Search consortium.
The World Intellectual Property Organization (WIPO), a UN
agency, was established in 1967 to promote the use of an interna-
tional intellectual property (IP) system to stimulate innovation and
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exploiting IP to address some of the world’s toughest challenges,
including public health (Dent et al., 2013). In 2011, WIPO, BIO Ven-
tures for Global Health (BVGH), and eight leading pharmaceutical
companies (Alnylam, AstraZeneca, Eisai, GlaxoSmithKline, MSD
[Merck], Novartis, Pﬁzer, and Sanoﬁ) established the WIPO
Re:Search consortium to facilitate access to the biopharmaceutical
industry’s IP assets. The Consortium’s objective is to leverage the IP
and product development expertise of biopharmaceutical compa-
nies to accelerate the development of new drugs, vaccines, and
diagnostics for NTDs, malaria, and tuberculosis. Through WIPO
Re:Search, biopharmaceutical companies share their IP assets, such
as compounds/compound libraries and data, as well as knowledge
and expertise, with academic and nonproﬁt neglected disease
researchers conducting novel product development projects.
Eligible research organizations join WIPO Re:Search as User,
Provider, and/or Supporter Members. Provider Members, such as
the founding biopharmaceutical companies, share their IP assets
with User Members. The User Members, such as universities and
nonproﬁt research institutes, utilize these IP assets to further their
discovery and development of products for the Consortium’s core
diseases. Supporter Members join WIPO Re:Search to demonstrate
their support of the Consortium’s activities and objectives. Prior to
joining, all Members must agree to abide by the WIPO Re:Search
Guiding Principles (Box 1). These Principles ensure that products
developed through WIPO Re:Search will be accessible to those
who need the products the most. In the three years since its launch,
the Consortium’s membership has expanded to over 90 for-proﬁt,
academic, nonproﬁt, and government research organizations.
These institutes span the globe – representing 24 countries from
















2014Box 1. The WIPO Re:Search Guiding Principles seek to ensure
that all products developed through Consortium partnerships
will be accessible to the individuals most affected by NTDs,
malaria, and tuberculosis. The Guiding Principles are not leg-
ally binding. Each WIPO Re:Search partnership is governed
by its specific agreement, however it is expected that these
agreements embody the spirit of the Guiding Principles.
The LDCs are the 49 countries identified and defined by the
United Nations Office of the High Representative for Least
Developed Countries, Landblocked Developing Countries
and the Small Island Developing States (UN-OHRLLS) as of
November 2010 (UN-OHRLLS, 2014). WIPO Re:Search
Guiding Principles:
 Members will provide a royalty-free license for any prod-
uct developed through WIPO Re:Search that is used and
sold in the least developed countries (LDCs).
 Members will consider the issue of access and affordabil-
ity to these products for all developing countries, includ-
ing those that do not qualify as LDCs.
 Members will provide royalty-free licenses for NTD,
malaria, and tuberculosis research and development.
 IP asset users will retain ownership of any new IP devel-
oped, but are encouraged to make new inventions avail-
able to other Members of WIPO Re:Search.0 2 4 6 8 10 12 14 16 18 
Malaria
Tuberculosis 
Number of WIPO Re:Search Partnerships
Fig. 1. WIPO Re:Search agreements by disease focus and calendar year established.
Since 2011, over 70 partnerships, representing one or more diseases, have been
ﬁnalized. Adapted with permission from Ramamoorthi et al. (2014). Copyright 2014
American Chemical Society.As the Secretariat of WIPO Re:Search, WIPO is responsible
for managing the WIPO Re:Search Database – an online database
of IP assets contributed by Members; coordinating regular com-
munication between WIPO, BVGH, and Members; and hosting
the annual Member meeting. BVGH is the Partnership HubAdministrator and is responsible for facilitating connections and
collaborations between Members, recruiting new Members, and
communicating the Consortium’s activities and achievements.
Established in 2004 by the Biotechnology Industry Organization
(BIO), BVGH’s mission is to engage biopharmaceutical companies
in global health initiatives. BVGH leverages its relationship with
biopharmaceutical companies and its background in global health
to facilitate meaningful WIPO Re:Search collaborations that accel-
erate product development projects.
WIPO Re:Search membership is free to all non-proﬁt, academic,
and government research organizations; for-proﬁt Members pro-
vide annual ﬁnancial sponsorship to the Consortium. This sponsor-
ship supports BVGH’s partnering activities. Scientists participating
in a WIPO Re:Search partnership are not only responsible for per-
forming the research and development activities but are also
responsible for securing funding to support these activities. Phar-
maceutical company partners have assisted in securing research
grants by providing their academic partners with letters of support
for inclusion in grant applications. BVGH also assists the research-
ers by providing all Members with access to its Funders Database, a
comprehensive compilation of funding awards relevant to
neglected infectious disease researchers.
WIPO Re:Search has expanded past its original vision of facili-
tating product development collaborations between pharmaceuti-
cal companies and academic researchers. Indeed, BVGH has
facilitated agreements between pharmaceutical companies and
biotech startups, as well as collaborations between two academic
institutions. Furthermore, to assist in the development of product
development skills in the developing world, WIPO and BVGH have
established several training opportunities for researchers from
African Member institutions. This article presents several examples
of collaborative research projects and short-term capacity-building
experiences between WIPO Re:Search Members that were facili-
tated by BVGH.2. WIPO Re:Search collaborations
Through its role as theWIPO Re:Search Partnership Hub Admin-
istrator, BVGH is tasked with establishing innovative research part-
nerships between Members. BVGH studies the scientiﬁc literature
published by Members’ scientists, identiﬁes areas of potential col-
laboration, and contacts the researchers to suggest partnership
ideas. This proactive partnering approach has proven to be highly
Fig. 2. Location of WIPO Re:Search anthelmintic drug development partnerships within the product development pipeline. The majority of partnerships facilitated to date
involve the sharing of compounds or compound libraries to be screened against the causative agents of schistosomiasis, soil-transmitted helminthiases, onchocerciasis,
lymphatic ﬁlariasis, and neurocysticercosis. Partners mentioned in this ﬁgure include Aberystwyth University, Alnylam Pharmaceuticals, AstraZeneca (AZ), Drugs for
Neglected Diseases initiative (DNDi), Eskitis Institute at Grifﬁth University, GlaxoSmithKline (GSK), Liverpool School of Tropical Medicine (Liverpool STM), McGill University,
MSD (known as Merck in the US and Canada), US National Institutes of Health (NIH), Swiss Tropical and Public Health Institute (Swiss TPH), University of British Columbia
(UBC), University of California, San Francisco (UCSF), and University of Buea. Capacity-building partnerships are not included in the ﬁgure. Asterisks (⁄, ⁄⁄, ⁄⁄⁄) represent
partnerships focused on multiple diseases.
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(Fig. 1). Eleven of these collaborations involve projects focused
on developing new anthelmintic drugs (Fig. 2). The following
describe three such WIPO Re:Search collaborations that were
established to accelerate drug discovery for schistosomiasis, soil-
transmitted helminthiases, and onchocerciasis.
Schistosomiasis (also known as bilharzia or snail fever) affects
over 249 million individuals worldwide (World Health
Organization, 2014a), predominantly in tropical and sub-tropical
regions. Symptoms associated with schistosomiasis include pain,
diarrhea, weakness, and hepatosplenomegaly, as well as anemia
and stunting in children (World Health Organization, 2014a). Pra-
ziquantel is the only widely-available and WHO-recommended
drug for treatment of the disease. This drug is thought to antago-
nize schistosome calcium ion channels, leading to paralysis of
adult worms’ muscles (Doenhoff et al., 2008) – however this has
not been demonstrated conclusively. Complicating its use, prazi-
quantel has only limited efﬁcacy against immature schistosome
worms (Pica-Mattoccia and Cioli, 2004; Botros et al., 2005). A
pediatric formulation of praziquantel is not yet available, however
an international public–private partnership, the Pediatric Prazi-
quantel Consortium, is reformulating the drug, or its active enan-
tiomer, for use in young children (TI Pharma, 2014). With the
substantial number of infections occurring annually, including in
children aged 65 years, and the prospect that over-reliance on a
single drug will lead to widespread resistance and an inability to
treat the disease, the need for a second, more broadly-acting drugthat can further reduce schistosomiasis morbidity in any age group
is required.
To address this, researchers at the Swiss Tropical and Public
Health Institute (Swiss TPH) exploited nature, speciﬁcally the Esk-
itis Institute’s Nature Bank, to identify new schistosomiasis drugs.
Based at Grifﬁth University in Australia, the Nature Bank includes
samples from marine organisms harvested from the Great Barrier
Reef and temperate reefs near Tasmania, and terrestrial plant sam-
ples collected from the forests of Papua New Guinea, South East
China, and Queensland, Australia. Combined, the Nature Bank has
45,000 samples from a total of >14,000 species of plants and mar-
ine organisms. In addition, 200,000 fractions and 3000 pure com-
pounds have been produced from these species (Camp et al.,
2014). BVGH facilitated an introduction between Prof. Jennifer
Keiser, a faculty member at Swiss TPH, and Prof. Ronald Quinn,
the Director of the Eskitis Institute, to explore a potential collabo-
ration. A material transfer agreement (MTA) was put in place that
allowed researchers at Swiss TPH to screen the Nature Bank’s
extracts against schistosomes and soil-transmitted helminths. In
the event that Swiss TPH identiﬁed any promising hits, the Eskitis
Institute offered to provide additional support to identify and
isolate the hits’ active components.
Soil-transmitted helminths (STHs), including Ascaris (round-
worm), Trichuris (whipworm), Necator, and Ancylostoma genera
(hookworms), are the most prevalent NTDs, resulting in 819 mil-
lion, 464.6 million, and 438.9 million infections in 2010, respec-
tively (Pullan et al., 2014). STHs are predominantly found in
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commonly coincide with areas of high poverty and poor sanitation
and hygiene. Symptoms associated with STH infection include
diarrhea, abdominal pain, general malaise and weakness, and in
the case of hookworm infection, chronic anemia (World Health
Organization, 2014b). Several drugs are currently available to treat
STH infections, including albendazole, mebendazole, pyrantel
pamoate, and levamisole, however none of these drugs is highly
effective against all three types of helminths (Adegnika et al.,
2014). There is only limited evidence of growing anthelmintic
resistance in the helminths (Vercruysse et al., 2012), however,
resistance in livestock has been demonstrated, further emphasiz-
ing the necessity of developing new, more broadly-acting drugs.
Caenorhabditis elegans has been utilized by scientists globally to
examine mechanisms of disease, to map signaling pathways, and
to elucidate cellular differentiation. The nematode is extremely
well characterized and scientists possess the techniques, tools,
and reagents that facilitate its facile maintenance and manipula-
tion. As a nematode, C. elegans is related to numerous pathogenic
helminths, including Ascaris, Trichuris, and hookworms, and thus
may be utilized as a model organism for STH biology. Due to its
ease of use, Prof. Joseph Dent and Prof. Tim Geary at McGill Univer-
sity have utilized C. elegans to screen potential STH drug candi-
dates. To demonstrate the feasibility of utilizing C. elegans in a
high-throughput screen (HTS), BVGH connected AstraZeneca and
Prof. Dent and Prof. Geary. Following discussions, researchers from
AstraZeneca and McGill collaborated within AstraZeneca’s Global
HTS Centre to screen a 7000-compound diversity library against
C. elegans as a proof of concept activity. The results of this study
were incorporated into an application that requested funding to
support the further screening of up to two million AstraZeneca
compounds within AstraZeneca’s HTS facility. AstraZeneca, Prof.
Dent, and Prof. Geary included the Eskitis Institute in this collabo-
ration in order to also screen the Nature Bank’s natural product
fractions against C. elegans. While the application was shortlisted,
it was not selected for funding. This result was not entirely dis-
couraging; both Prof. Dent and Prof. Geary expressed a willingness
to develop a new strategy to move the project with AstraZeneca
and the Eskitis Institute forward.
Onchocerciasis (river blindness), second only to trachoma as the
leading cause of infectious blindness (Etya’ale, 2002; Centers for
Disease Control and Prevention, 2013), is caused by the nematode
worm, Onchocerca volvulus. The infection is managed in endemic
areas through annual or semi-annual MDA of the broad-spectrum
anthelmintic, ivermectin. Ivermectin treatment results in the
hyperpolarization of Onchocerca glutamate-sensitive channels,
which paralyzes the movement and pharyngeal pumping of imma-
ture worms (microﬁlariae) (Wolstenholme and Rogers, 2005).
Movement and pharyngeal pumping are not required for adult
worm (macroﬁlariae) survival, and as such, while ivermectin treat-
ment results in a substantial (98%) reduction in dermal microﬁlar-
iae (Basanez et al., 2008), it has a limited effect on macroﬁlariae
(Taylor et al., 2010). In contrast, concurrent administration of the
antibiotic, doxycycline, results in a reduction in female macroﬁla-
riae reproduction and eventual death of the adult worms. How-
ever, doxycycline, which targets the helminth’s essential
intracellular Wolbachia bacteria, requires a four- to six-week
course of daily administrations and is contraindicated in children
and pregnant women (Tamarozzi et al., 2011). This limits the anti-
biotic’s utility in MDA programs. Furthermore, high Onchocerca
microﬁlariae burden and Loa loa coinfection both have been asso-
ciated with severe adverse events to ivermectin (Boussinesq et al.,
2003; Merck, 2010; Taylor et al., 2010; Turner et al., 2010), thus
limiting the regions where ivermectin can be used safely. Given
the complications and regimens of existing drugs, there is asubstantial need for new and effective treatments for
onchocerciasis.
Researchers at the University of Buea, in Cameroon, have devel-
oped a medium-throughput phenotypic assay to screen com-
pounds and natural product extracts against Onchocerca worms.
Speciﬁcally, natural products are screened against Onchocerca och-
engi microﬁlariae and macroﬁlariae isolated from cows at local
abattoirs, as well as counter-screened against Loa loa microﬁlariae
isolated from humans. This tripartite screen ensures that com-
pounds displaying micro- and macroﬁlaricidal activities are inac-
tive against the Loa loa ﬁlariae. Prof. Fidelis Cho-Ngwa identiﬁed
several natural products with activity against the microﬁlariae
and macroﬁlariae. To aid in the further development of these
potential anti-onchocercal natural product extracts, BVGH con-
nected Prof. Cho-Ngwa with a researcher from the University of
British Columbia (UBC) in Canada. The UBC faculty member, Prof.
Raymond Andersen, is an organic chemist by training and has
the essential technologies, expertise, and experience needed to
identify active compounds from natural product extracts. Through
WIPO Re:Search, Prof. Andersen will assist with activity-guided
fractionation to isolate and subsequently characterize the extracts’
active compounds.
These collaborations are just a few examples of the numerous
partnerships that WIPO Re:Search Members are participating in.
While these projects were developed on an ad hoc basis, driven
by the interests and expertise of the researchers rather than to
speciﬁcally ﬁll a product pipeline, as evidenced by Fig. 2, the
partnerships are clearly contributing to the product development
pipeline. Bringing a product through preclinical, clinical, and
regulatory ﬁling activities is an inherently expensive endeavor that
requires signiﬁcant expertise. In the event that a WIPO Re:Search
partnership results in a promising lead, BVGH will work with the
participating Members to identify sources of funding as well as
other Members with the expertise needed to transit the potential
product through the pipeline to the market and those individuals
that need it the most.
3. WIPO Re:Search capacity-building experiences
Cutting edge skills and knowledge, such as biopharmaceutical
industry expertise, are essential for researchers to efﬁciently trans-
late a novel ﬁnding into a new product. In addition to facilitating
collaborative research projects betweenWIPO Re:Search Members,
BVGH has also organized short-term capacity-building experiences
for ﬁve African scientists at biopharmaceutical companies and
leading academic institutions. These training experiences were
implemented with ﬁnancial support from the Australian Govern-
ment Funds in Trust through WIPO. Through these training experi-
ences, the scientists gained the skills and knowledge needed to
move their research at their home institutions forward. The follow-
ing are three examples of the research undertaken during these
training experiences.
In addition to the symptoms of schistosomiasis mentioned
above, Schistosoma haematobium infection has been associated
with an increased incidence of bladder carcinomas. These carcino-
mas are thought to be induced by schistosome-mediated chronic
irritation and inﬂammation of the bladder, and may be further
exacerbated by bacterial coinfection. In schistosomiasis-endemic
regions, such as Egypt, approximately 30% of all cancers are blad-
der cancers associated with schistosomiasis (Mostafa et al.,
1999). While expansive epidemiological data demonstrate the con-
nection between S. haematobium infection and bladder cancer, the
histopathological effect of schistosomiasis on the bladder and the
molecular mechanisms of its carcinogenesis are not fully under-
stood (Honeycutt, 2014).
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miasis pathology from the Theodor Bilharz Research Institute
(TBRI) in Giza, Egypt, participated in a WIPO Re:Search capacity-
building experience at Stanford University. Prof. Michael Hsieh at
Stanford had developed a microsurgery technique that recapitu-
lated human schistosome bladder infections in mice (Fu et al.,
2012). Through the capacity-building placement, Prof. Hammam
used her experience as a pathologist to examine bladder carcino-
mas associated with schistosomiasis, and in partnership with Prof.
Hsieh, investigated whether these carcinomas were directly caused
by schistosome infection.
Female genital schistosomiasis caused by S. haematobium infec-
tion has additionally been associated with increased susceptibility
to HIV infection (Feldmeier et al., 1994; Kjetland et al., 2006;
Mbabazi et al., 2011). While at Stanford, Prof. Hammam also par-
ticipated in the development of a murine model of female genital
schistosomiasis that will aid in the exploration of the mechanisms
of female genital schistosomiasis and its role in increased HIV
susceptibility (Richardson et al., 2014).
Researchers at the Kwame Nkrumah University of Science and
Technology (KNUST) in Kumasi, Ghana specialize in examining
the potential of natural products and medicinal plants as anti-
microbial and anti-parasitic treatments. In order to stimulate
KNUST’s discovery of anti-parasitic compounds, Dr. Christian Agy-
are, a KNUST senior lecturer, participated in a WIPO Re:Search
capacity-building experience at the Center for Discovery and Inno-
vation in Parasitic Diseases (CDIPD) at the University of California,
San Francisco (UCSF), in collaboration with Dr. Conor Caffrey. The
training program provided Dr. Agyare with experience cultivating,
maintaining, and screening compounds against numerous para-
sites, including the causative agents of Chagas disease, lymphatic
ﬁlariasis, human African trypanosomiasis, and schistosomiasis.
During the capacity-building placement, Ghanaian natural
products were screened against the various parasitic organisms.
Following the extraction and puriﬁcation of compounds from those
anti-parasitic products at KNUST, Dr. Agyare will return to UCSF to
further examine their anti-parasitic activity. The skills and training
acquired during the capacity-building placement will enhance the
research program and education of undergraduate and post-
graduate students at KNUST. Dr. Agyare and Dr. Caffrey’s long-term
goal is to maintain and expand the collaborative activities between
KNUST and UCSF.
BVGH also facilitated the placement of Prof. Fidelis Cho-Ngwa at
Novartis’ headquarters in Basel, Switzerland. The three-month
capacity-building experience provided Prof. Cho-Ngwa with the
opportunity to work alongside Novartis scientists to obtain the
knowledge and skills necessary to use HPLC and MS techniques
to extract, purify, and identify the active compounds from natural
products identiﬁed during his tripartite anti-onchocercal pheno-
typic screen.
Capacity-building opportunities such as these enable
developing country researchers to learn the advanced laboratory
techniques and product development processes essential to
move their projects forward. These experiences foster international
collaboration and cooperation, and increase the skills and
capabilities of laboratories across the region, thus allowing
these institutes and researchers to be active contributors to the
global movement to eliminate the health inequalities of the
developing world.
4. Conclusion
It is abundantly clear that new anthelmintic drugs are needed.
Helminth infections represent a serious health and economic bur-
den on individuals and communities living in poverty. They hinder
childhood development, limit school attendance, and prevent asubstantial section of the adult population from supporting their
countries’ economic development (Hotez et al., 2008). Current
anthelmintic regimens are burdened with incomplete coverage
across all genera (Adegnika et al., 2014), and/or life cycle stages
(Pica-Mattoccia and Cioli, 2004; Botros et al., 2005); limiting con-
traindications (Tamarozzi et al., 2011) and serious side-effects
(Boussinesq et al., 2003; Taylor et al., 2010; Turner et al., 2010);
long treatment dosing regimens (Tamarozzi et al., 2011); and the
potential for the development of resistance (Vercruysse et al.,
2012). As the Partnership Hub Administrator of WIPO Re:Search,
BVGH facilitates meaningful partnerships between neglected dis-
ease researchers and biopharmaceutical companies with com-
pounds to repurpose, data to utilize, and expertise to share.
Through these partnerships, scientists are furthering their under-
standing of helminths and moving closer to developing new
anthelmintic drugs.
In addition to the partnerships discussed in this article, BVGH is
also establishing WIPO Re:Search collaborations that advance the
development of helminth diagnostics. These include diagnostics
that will be used during the transition from disease control to elim-
ination, when testing before treatment becomes more important.
The innovation spurred by the collaborations facilitated between
pharmaceutical and biotechnology companies, academic institu-
tions, and government organizations will prove essential to the
development of products that eliminate the helminthic diseases
that exact a devastating toll on those living in poverty. By doing
so, these, and other, collaborations pave the way for improved
health and economic growth across the globe.
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